---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-117578"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2024-10-28T23:59:59+00:00"
generated_at: "2026-05-30T09:47:59.029980+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Candel reports 3 of 6 rHGG patients alive >1 year after CAN-3110 multiple injections

## Summary
- Phase 1b trial of CAN-3110 in recurrent high-grade glioma: 3/6 patients alive at 12.2, 13.0, and 18.7 months post-treatment.
- Data show improved survival vs. historical controls; biopsies reveal near absence of tumor cells with dense lymphocyte infiltrates.
- Radiologic pseudo-progression observed: post-treatment MRI enhancement despite tumor clearance on histology.
- Presented at 2024 IOVC; also disclosed new IL-12/IL-15 multimodal immunotherapy candidate from enLIGHTEN platform.

## SEC filing metadata
- accession: 0000950170-24-117578
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2024-10-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017024117578/0000950170-24-117578-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017024117578/cadl-20241028.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-117578
- JSON: https://secwatch.observer/filing/0000950170-24-117578.json
- Plain text: https://secwatch.observer/filing/0000950170-24-117578.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.